AstraZeneca To Challenge GSK After Clinching Lupus Drug Approval
FDA Gives Green Light To Saphnelo
Executive Summary
Fears that US regulators would take issue with AstraZeneca's decision to change the endpoints of a second pivotal trial for anifrolumab were unfounded and the first-in-class type I interferon inhibitor is the first new treatment for systemic lupus erythematosus in more than 10 years.
You may also be interested in...
Idorsia Advances Lupus Drug Into Phase III Despite Mid-Stage Fail
The Swiss biotech is confident its S1P1 receptor modulator can be an effective treatment for lupus but the move into late-stage studies has raised some eyebrows.
AstraZeneca Rejigs Respiratory Franchise With Fresh Covis Deal
Having got hold of two COPD drugs from Spain's Almirall in 2014, AstraZeneca has passed Eklira and Duaklir onto old partner Covis Pharma as it focuses on more targeted respiratory therapies.
Keeping Track: US FDA Approvals Of Saphnelo, Nexviazyme Balanced By CRLs For Rolontis, Treosulfan, Tenapanor
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.